Severe Asthma
A Managed Access Protocol (MAP) is in place for medicines for the treatment of severe asthma. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of benralizumab, dupilumab, mepolizumab and tezepelumab on the High Tech Arrangement and benralizumab, mepolizumab and reslizumab under Hospital Pricing Approval.
Applications for reimbursement approval for benralizumab, dupilumab, mepolizumab, reslizumab and tezepelumab for the treatment of severe asthma under the High Tech Arrangement / Hospital Pricing Approval will only be considered from consultant respiratory physicians or consultant paediatricians with a special interest in respiratory medicine, with specialist registration with the Irish Medical Council in the specialities of respiratory medicine or paediatrics, who specialise in severe asthma and are practicing within a severe asthma centre, and who have agreed to the terms of this MAP and been approved by the HSE. The approved consultant must submit an application for individual reimbursement approval for each patient.
A copy of the MAP for Medicines for the Treatment of Severe Asthma can be found in the Related Files section below.
For further information, please contact mmp@hse.ie.